1
|
Nano-Nutraceuticals for Health: Principles and Applications. REVISTA BRASILEIRA DE FARMACOGNOSIA : ORGAO OFICIAL DA SOCIEDADE BRASILEIRA DE FARMACOGNOSIA 2023; 33:73-88. [PMID: 36466145 PMCID: PMC9684775 DOI: 10.1007/s43450-022-00338-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 11/08/2022] [Indexed: 11/24/2022]
Abstract
The use of nanotechnological products is increasing steadily. In this scenario, the application of nanotechnology in food science and as a technological platform is a reality. Among the several applications, the main use of this technology is for the development of foods and nutraceuticals with higher bioavailability, lower toxicity, and better sustainability. In the health field, nano-nutraceuticals are being used as supplementary products to treat an increasing number of diseases. This review summarizes the main concepts and applications of nano-nutraceuticals for health, with special focus on treating cancer and inflammation. Graphical abstract Supplementary Information The online version contains supplementary material available at 10.1007/s43450-022-00338-7.
Collapse
|
2
|
Kido LA, Hahm ER, Kim SH, Baseggio AM, Cagnon VHA, Singh SV, Maróstica MR. Prevention of Prostate Cancer in Transgenic Adenocarcinoma of the Mouse Prostate Mice by Yellow Passion Fruit Extract and Antiproliferative Effects of Its Bioactive Compound Piceatannol. J Cancer Prev 2020; 25:87-99. [PMID: 32647650 PMCID: PMC7337005 DOI: 10.15430/jcp.2020.25.2.87] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 05/19/2020] [Accepted: 05/20/2020] [Indexed: 01/10/2023] Open
Abstract
Piceatannol (PIC), a polyphenol presents in many vegetables and fruits including yellow passion fruit extract (PFE; Passiflora edulis), has anti-cancer activity, but its molecular targets are still poorly understood. The aims of this study were to investigate the molecular mechanistic actions of PIC in prostate cancer cell lines and to test if the extract from PFE rich in PIC can affect the growth of prostate cancer cells in the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model. The PC-3, 22Rv1, LNCaP, and VCaP prostate cancer cells were exposed to PIC (10-40 μM), and cell viability, lactate measurement, Western blot, and flow cytometric analyses were performed. For an in vivo experiments, eight-week-old TRAMP mice (n = 10 per group each) received an aqueous extract of PFE containing 20 mg of PIC/kg or water (control group) by gavage for 4 or 10 weeks for further analyses. PIC treatment concentration- and time-dependently reduced viability of all cell lines tested. 22Rv1 and LNCaP cells treated with PIC did not exhibit any significant alteration in the intracellular accumulation of lactate. PIC treatment caused G0/G1 phase cell cycle arrest and induction of apoptosis in both LNCaP and 22Rv1 cells. PIC-treated cells exhibited altered protein levels of p53, p21, cyclin D1, and cyclin-dependent kinase 4 (cdk4). The short and long-term PFE treatments also affected p21, cyclin D1 and cdk4 and delayed disease progression in TRAMP, with a decreased incidence of preneoplastic lesions. In conclusion, PIC apparently does not alter glucose metabolism in prostate cancer cells, while cell cycle arrest and p53 modulation are likely important in anti-cancer effects of PIC alone or as a food matrix byproduct in prostate cancer cells, especially those with an androgen-dependent phenotype.
Collapse
Affiliation(s)
- Larissa Akemi Kido
- Department of Food and Nutrition, Faculty of Food Engineering, University of Campinas, Campinas, Brazil.,Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil
| | | | - Su-Hyeong Kim
- Department of Pharmacology and Chemical Biology, PA, USA
| | - Andressa Mara Baseggio
- Department of Food and Nutrition, Faculty of Food Engineering, University of Campinas, Campinas, Brazil
| | - Valeria Helena Alves Cagnon
- Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - Shivendra V Singh
- Department of Pharmacology and Chemical Biology, PA, USA.,UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Mário Roberto Maróstica
- Department of Food and Nutrition, Faculty of Food Engineering, University of Campinas, Campinas, Brazil
| |
Collapse
|
3
|
Rahman HS, Othman HH, Hammadi NI, Yeap SK, Amin KM, Abdul Samad N, Alitheen NB. Novel Drug Delivery Systems for Loading of Natural Plant Extracts and Their Biomedical Applications. Int J Nanomedicine 2020; 15:2439-2483. [PMID: 32346289 PMCID: PMC7169473 DOI: 10.2147/ijn.s227805] [Citation(s) in RCA: 72] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Accepted: 10/10/2019] [Indexed: 12/18/2022] Open
Abstract
Many types of research have distinctly addressed the efficacy of natural plant metabolites used for human consumption both in cell culture and preclinical animal model systems. However, these in vitro and in vivo effects have not been able to be translated for clinical use because of several factors such as inefficient systemic delivery and bioavailability of promising agents that significantly contribute to this disconnection. Over the past decades, extraordinary advances have been made successfully on the development of novel drug delivery systems for encapsulation of plant active metabolites including organic, inorganic and hybrid nanoparticles. The advanced formulas are confirmed to have extraordinary benefits over conventional and previously used systems in the manner of solubility, bioavailability, toxicity, pharmacological activity, stability, distribution, sustained delivery, and both physical and chemical degradation. The current review highlights the development of novel nanocarrier for plant active compounds, their method of preparation, type of active ingredients, and their biomedical applications.
Collapse
Affiliation(s)
- Heshu Sulaiman Rahman
- Department of Physiology, College of Medicine, University of Sulaimani, Sulaymaniyah46001, Republic of Iraq
- Department of Medical Laboratory Sciences, College of Health Sciences, Komar University of Science and Technology, Sulaymaniyah, Republic of Iraq
| | - Hemn Hassan Othman
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaymaniyah46001, Republic of Iraq
| | - Nahidah Ibrahim Hammadi
- Department of Histology, College of Veterinary Medicine, University of Al-Anbar, Ramadi, Republic of Iraq
| | - Swee Keong Yeap
- China-ASEAN College of Marine Sciences, Xiamen University Malaysia, Sepang, Malaysia
| | - Kawa Mohammad Amin
- Department of Microbiology, College of Medicine, University of Sulaimani, Sulaymaniyah46001, Republic of Iraq
| | - Nozlena Abdul Samad
- Integrative Medicine Cluster, Institut Perubatan dan Pergigian Termaju (IPPT), Sains@BERTAM, Universiti Sains Malaysia, Kepala Batas13200, Pulau Pinang, Malaysia
| | - Noorjahan Banu Alitheen
- Department of Cell and Molecular Biology, Faculty of Biotechnology and Bio-Molecular Sciences, Universiti Putra Malaysia, Selangor, Malaysia
| |
Collapse
|
4
|
Wang Y, Kan Z, Wan X, McGinley JN, Thompson HJ. Differences in chemical composition predictive of in vitro biological activity among commercially important cultivars of genus Camellia. Food Chem 2019; 297:124950. [PMID: 31253304 DOI: 10.1016/j.foodchem.2019.06.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Revised: 05/24/2019] [Accepted: 06/05/2019] [Indexed: 12/22/2022]
Abstract
Leaves of plants from the genus Camellia (CAM) are used to make tea; however, there are limited data that compares chemical composition and biological activity of CAM cultivars used to make six tea types. Fourteen CAM cultivars were analyzed by HPLC and UPLC-Q-TOF-MS/MS and biological activity was assessed in a cell growth assay. Tea bioactives and cell growth inhibition varied 2-4 fold. EGCG was the dominant catechin that predicted the magnitude of growth inhibition. However, pure EGCG did not fully account for inhibitory activity suggesting that it may serve as a chemical marker for bioefficacy. As an unbiased characterization of differences in chemical composition among CAM, individual metabolomes were determined and used to generate principle components (PC). PC's from the metabolome were complementary to those from targeted analyses of tea bioactives and were predictive of growth inhibition. This study provides a frame work for identifying CAM cultivars with beneficial traits.
Collapse
Affiliation(s)
- Yijun Wang
- International Joint Laboratory on Tea Chemistry and Health Effects, State Key Laboratory of Tea Plant Biology and Utilization, Anhui Agricultural University, Hefei, PR China
| | - Zhipeng Kan
- International Joint Laboratory on Tea Chemistry and Health Effects, State Key Laboratory of Tea Plant Biology and Utilization, Anhui Agricultural University, Hefei, PR China
| | - Xiaochun Wan
- International Joint Laboratory on Tea Chemistry and Health Effects, State Key Laboratory of Tea Plant Biology and Utilization, Anhui Agricultural University, Hefei, PR China
| | - John N McGinley
- Cancer Prevention Laboratory, Colorado State University, Fort Collins, CO, USA
| | - Henry J Thompson
- Cancer Prevention Laboratory, Colorado State University, Fort Collins, CO, USA.
| |
Collapse
|
5
|
Rhodiola rosea L.: an herb with anti-stress, anti-aging, and immunostimulating properties for cancer chemoprevention. ACTA ACUST UNITED AC 2017; 3:384-395. [PMID: 30393593 DOI: 10.1007/s40495-017-0106-1] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Purpose of review Rhodiola rosea extracts have been used as a dietary supplement in healthy populations, including athletes, to non-specifically enhance the natural resistance of the body to both physical and behavior stresses for fighting fatigue and depression. We summarize the information with respect to the new pharmacological activities of Rhodiola rosea extracts and its underlying molecular mechanisms in this review article. Recent findings In addition to its multiplex stress-protective activity, Rhodiola rosea extracts have recently demonstrated its anti-aging, anti-inflammation, immunostimulating, DNA repair and anti-cancer effects in different model systems. Molecular mechanisms of Rhodiola rosea extracts's action have been studied mainly along with one of its bioactive compounds, salidroside. Both Rhodiola rosea extracts and salidroside have contrast molecular mechanisms on cancer and normal physiological functions. For cancer, Rhodiola rosea extracts and salidroside inhibit the mTOR pathway and reduce angiogenesis through down-regulation of the expression of HIF-1α/HIF-2α. For normal physiological functions, Rhodiola rosea extracts and salidroside activate the mTOR pathway, stimulate paracrine function and promote neovascularization by inhibiting PHD3 and stabilizing HIF-1α proteins in skeletal muscles. In contrast to many natural compounds, salidroside is water-soluble and highly bioavailable via oral administration and concentrated in urine by kidney excretion. Summary Rhodiola rosea extracts and salidroside can impose cellular and systemic benefits similar to the effect of positive lifestyle interventions to normal physiological functions and for anti-cancer. The unique pharmacological properties of Rhodiola rosea extracts or salidroside deserve further investigation for cancer chemoprevention, in particular for human urinary bladder cancer.
Collapse
|
6
|
Rady I, Siddiqui IA, Rady M, Mukhtar H. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett 2017; 402:16-31. [PMID: 28536009 DOI: 10.1016/j.canlet.2017.05.010] [Citation(s) in RCA: 189] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Revised: 05/11/2017] [Accepted: 05/12/2017] [Indexed: 02/07/2023]
Abstract
Melittin (MEL), a major peptide component of bee venom, is an attractive candidate for cancer therapy. This agent has shown a variety of anti-cancer effects in preclinical cell culture and animal model systems. Despite a convincing efficacy data against variety of cancers, its applicability to humans has met with challenges due to several issues including its non-specific cytotoxicity, degradation and hemolytic activity. Several optimization approaches including utilization of nanoparticle based delivery of MEL have been utilized to circumvent the issues. Here, we summarize the current understanding of the anticancer effects of bee venom and MEL on different kinds of cancers. Further, we also present the available information for the possible mechanism of action of bee venom and/or MEL.
Collapse
Affiliation(s)
- Islam Rady
- School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, WI 53706, USA; Department of Zoology, Faculty of Science, Al-Azhar University, Cairo, Egypt
| | - Imtiaz A Siddiqui
- School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, WI 53706, USA
| | - Mohamad Rady
- Department of Zoology, Faculty of Science, Al-Azhar University, Cairo, Egypt
| | - Hasan Mukhtar
- School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, WI 53706, USA.
| |
Collapse
|
7
|
Sanna V, Singh CK, Jashari R, Adhami VM, Chamcheu JC, Rady I, Sechi M, Mukhtar H, Siddiqui IA. Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy. Sci Rep 2017; 7:41573. [PMID: 28145499 PMCID: PMC5286400 DOI: 10.1038/srep41573] [Citation(s) in RCA: 65] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Accepted: 12/20/2016] [Indexed: 01/15/2023] Open
Abstract
Earlier we introduced the concept of ‘nanochemoprevention’ i.e. the use of nanotechnology to improve the outcome of cancer chemoprevention. Here, we extended our work and developed polymeric EGCG-encapsulated nanoparticles (NPs) targeted with small molecular entities, able to bind to prostate specific membrane antigen (PSMA), a transmembrane protein that is overexpressed in prostate cancer (PCa), and evaluated their efficacy in preclinical studies. First, we performed a molecular recognition of DCL- and AG-PEGylation on ligand binding on PSMA active site. Next, the biocompatible polymers PLGA-PEG-A were synthesized and used as base to conjugate DCL or AG to obtain the respective copolymers, needed for the preparation of targeted NPs. The resulting EGCG encapsulating NPs led to an enhanced anti-proliferative activity in PCa cell lines compared to the free EGCG. The behavior of EGCG encapsulated in NPs in modulating apoptosis and cell-cycle, was also determined. Then, in vivo experiments, in mouse xenograft model of prostatic tumor, using EGCG-loaded NPs, with a model of targeted nanosystems, were conducted. The obtained data supported our hypothesis of target-specific enhanced bioavailability and limited unwanted toxicity, thus leading to a significant potential for probable clinical outcome.
Collapse
Affiliation(s)
- Vanna Sanna
- Department of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, 07100 Sassari, Italy
| | - Chandra K Singh
- School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, Madison WI 53706, USA
| | - Rahime Jashari
- School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, Madison WI 53706, USA
| | - Vaqar M Adhami
- School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, Madison WI 53706, USA
| | - Jean Christopher Chamcheu
- School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, Madison WI 53706, USA
| | - Islam Rady
- School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, Madison WI 53706, USA.,Department of Zoology, University of AL-Azhar, Cairo, Egypt
| | - Mario Sechi
- Department of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, 07100 Sassari, Italy
| | - Hasan Mukhtar
- School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, Madison WI 53706, USA
| | - Imtiaz A Siddiqui
- School of Medicine and Public Health, Department of Dermatology, University of Wisconsin-Madison, Madison WI 53706, USA
| |
Collapse
|
8
|
Ullah MF, Bhat SH, Husain E, Abu-Duhier F, Hadi SM, Sarkar FH, Ahmad A. Pharmacological Intervention through Dietary Nutraceuticals in Gastrointestinal Neoplasia. Crit Rev Food Sci Nutr 2017; 56:1501-18. [PMID: 25365584 DOI: 10.1080/10408398.2013.772091] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Neoplastic conditions associated with gastrointestinal (GI) tract are common worldwide with colorectal cancer alone accounting for the third leading rate of cancer incidence. Other GI malignancies such as esophageal carcinoma have shown an increasing trend in the last few years. The poor survival statistics of these fatal cancer diseases highlight the need for multiple alternative treatment options along with effective prophylactic strategies. Worldwide geographical variation in cancer incidence indicates a correlation between dietary habits and cancer risk. Epidemiological studies have suggested that populations with high intake of certain dietary agents in their regular meals have lower cancer rates. Thus, an impressive embodiment of evidence supports the concept that dietary factors are key modulators of cancer including those of GI origin. Preclinical studies on animal models of carcinogenesis have reflected the pharmacological significance of certain dietary agents called as nutraceuticals in the chemoprevention of GI neoplasia. These include stilbenes (from red grapes and red wine), isoflavones (from soy), carotenoids (from tomatoes), curcuminoids (from spice turmeric), catechins (from green tea), and various other small plant metabolites (from fruits, vegetables, and cereals). Pleiotropic action mechanisms have been reported for these diet-derived chemopreventive agents to retard, block, or reverse carcinogenesis. This review presents a prophylactic approach to primary prevention of GI cancers by highlighting the translational potential of plant-derived nutraceuticals from epidemiological, laboratory, and clinical studies, for the better management of these cancers through consumption of nutraceutical rich diets and their intervention in cancer therapeutics.
Collapse
Affiliation(s)
- Mohammad F Ullah
- a Prince Fahad Research Chair , Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk , Tabuk , Saudi Arabia
| | - Showket H Bhat
- a Prince Fahad Research Chair , Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk , Tabuk , Saudi Arabia
| | - Eram Husain
- a Prince Fahad Research Chair , Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk , Tabuk , Saudi Arabia
| | - Faisel Abu-Duhier
- a Prince Fahad Research Chair , Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk , Tabuk , Saudi Arabia
| | - S M Hadi
- b Department of Biochemistry , Faculty of Life Sciences, Aligarh Muslim University , Uttar Pradesh , India
| | - Fazlul H Sarkar
- c Department of Pathology , Karmanos Cancer Institute, Wayne State University School of Medicine , Detroit , Michigan USA
| | - Aamir Ahmad
- c Department of Pathology , Karmanos Cancer Institute, Wayne State University School of Medicine , Detroit , Michigan USA
| |
Collapse
|
9
|
Siddiqui IA, Sanna V. Impact of nanotechnology on the delivery of natural products for cancer prevention and therapy. Mol Nutr Food Res 2016; 60:1330-41. [DOI: 10.1002/mnfr.201600035] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Revised: 01/26/2016] [Accepted: 01/28/2016] [Indexed: 12/11/2022]
Affiliation(s)
| | - Vanna Sanna
- Department of Chemistry and Pharmacy, Laboratory of Nanomedicine; University of Sassari; Sassari Italy
| |
Collapse
|
10
|
Siddiqui IA, Sanna V. Impact of nanotechnology on the delivery of natural products for cancer prevention and therapy. Mol Nutr Food Res 2016. [DOI: 10.1002/mnfr.201600035 pmid: 26935239] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Vanna Sanna
- Department of Chemistry and Pharmacy, Laboratory of Nanomedicine; University of Sassari; Sassari Italy
| |
Collapse
|
11
|
Meyskens FL, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS. Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst 2016; 108:djv309. [PMID: 26547931 PMCID: PMC4907357 DOI: 10.1093/jnci/djv309] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2015] [Revised: 07/18/2015] [Accepted: 09/28/2015] [Indexed: 12/13/2022] Open
Abstract
Approaches to reduce the global burden of cancer include two major strategies: screening and early detection and active preventive intervention. The latter is the topic of this Commentary and spans a broad range of activities. The genetic heterogeneity and complexity of advanced cancers strongly support the rationale for early interruption of the carcinogenic process and an enhanced focus on prevention as a priority strategy to reduce the burden of cancer; however, the focus of cancer prevention management should be on individuals at high risk and on primary localized disease in which screening and detection should also play a vital role. The timing and dose of (chemo-)preventive intervention also affects response. The intervention may be ineffective if the target population is very high risk or already presenting with preneoplastic lesions with cellular changes that cannot be reversed. The field needs to move beyond general concepts of carcinogenesis to targeted organ site prevention approaches in patients at high risk, as is currently being done for breast and colorectal cancers. Establishing the benefit of new cancer preventive interventions will take years and possibly decades, depending on the outcome being evaluated. We also propose that comparative effectiveness research designs and the value of information obtained from large-scale prevention studies are necessary in order for preventive interventions to become a routine part of cancer management.
Collapse
Affiliation(s)
- Frank L Meyskens
- Biological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY).
| | - Hasan Mukhtar
- Biological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY)
| | - Cheryl L Rock
- Biological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY)
| | - Jack Cuzick
- Biological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY)
| | - Thomas W Kensler
- Biological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY)
| | - Chung S Yang
- Biological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY)
| | - Scott D Ramsey
- Biological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY)
| | - Scott M Lippman
- Biological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY)
| | - David S Alberts
- Biological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY)
| |
Collapse
|
12
|
Siddiqui IA, Sanna V, Ahmad N, Sechi M, Mukhtar H. Resveratrol nanoformulation for cancer prevention and therapy. Ann N Y Acad Sci 2015; 1348:20-31. [DOI: 10.1111/nyas.12811] [Citation(s) in RCA: 110] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 05/13/2015] [Accepted: 05/18/2015] [Indexed: 12/17/2022]
Affiliation(s)
- Imtiaz A. Siddiqui
- School of Medicine and Public Health, Department of Dermatology; University of Wisconsin-Madison; Madison Wisconsin
| | - Vanna Sanna
- Department of Chemistry and Pharmacy, Laboratory of Nanomedicine; University of Sassari; Sassari Italy
| | - Nihal Ahmad
- School of Medicine and Public Health, Department of Dermatology; University of Wisconsin-Madison; Madison Wisconsin
| | - Mario Sechi
- Department of Chemistry and Pharmacy, Laboratory of Nanomedicine; University of Sassari; Sassari Italy
| | - Hasan Mukhtar
- School of Medicine and Public Health, Department of Dermatology; University of Wisconsin-Madison; Madison Wisconsin
| |
Collapse
|
13
|
Adhami VM, Bailey HH, Mukhtar H. Cancer chemoprevention is not a failure. Carcinogenesis 2014; 35:2154-5. [PMID: 24970761 DOI: 10.1093/carcin/bgu141] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Vaqar Mustafa Adhami
- Department of Dermatology, School of Medicine and Public Health, University of Wisconsin Medical Sciences Centre, Room 4385, 1300 University Avenue, Madison, WI 53706, USA and
| | - Howard H Bailey
- UW Carbone Cancer Center, University of Wisconsin, Madison, WI 53706, USA
| | - Hasan Mukhtar
- Department of Dermatology, School of Medicine and Public Health, University of Wisconsin Medical Sciences Centre, Room 4385, 1300 University Avenue, Madison, WI 53706, USA and UW Carbone Cancer Center, University of Wisconsin, Madison, WI 53706, USA
| |
Collapse
|
14
|
Kim SJ, Amankwah E, Connors S, Park HY, Rincon M, Cornnell H, Chornokur G, Hashim AI, Choi J, Tsai YY, Engelman RW, Kumar N, Park JY. Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice. Cancer Prev Res (Phila) 2014; 7:435-44. [PMID: 24501325 DOI: 10.1158/1940-6207.capr-13-0427-t] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Prostate cancer treatment is often accompanied by untoward side effects. Therefore, chemoprevention to reduce the risk and inhibit the progression of prostate cancer may be an effective approach to reducing disease burden. We investigated the safety and efficacy of Polyphenon E, a green tea extract, in reducing the progression of prostate cancer in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. A total of 119 male TRAMP and 119 C57BL/6J mice were treated orally with one of 3 doses of Polyphenon E (200, 500, and 1,000 mg/kg/day) in drinking water ad libitum replicating human achievable doses. Baseline assessments were performed before treatments. Safety and efficacy assessments during treatments were performed when mice were 12, 22, and 32 weeks old. The number and size of tumors in treated TRAMP mice were significantly decreased compared with untreated animals. In untreated 32 weeks old TRAMP mice, prostate carcinoma metastasis to distant sites was observed in 100% of mice (8/8), compared with 13% of mice (2/16) treated with high-dose Polyphenon E during the same period. Furthermore, Polyphenon E treatment significantly inhibited metastasis in TRAMP mice in a dose-dependent manner (P = 0.0003). Long-term (32 weeks) treatment with Polyphenon E was safe and well tolerated with no evidence of toxicity in C57BL/6J mice. Polyphenon E is an effective chemopreventive agent in preventing the progression of prostate cancer to metastasis in TRAMP mice. Polyphenon E showed no toxicity in these mouse models. Our findings provide additional evidence for the safety and chemopreventive effect of Polyphenon E in preventing metastatic progression of prostate cancer.
Collapse
Affiliation(s)
- Seung Joon Kim
- Department of Cancer Epidemiology, Moffitt Cancer Center, University of South Florida, College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Nagayama M, Yanagawa Y, Aihara K, Watanabe S, Takemoto M, Nakazato T, Hashimoto T, Takayama T, Takazawa Y, Iba T, Kaneko K, Tanaka H. Analysis of non-traumatic truncal back pain in patients who visited an emergency room. Acute Med Surg 2014; 1:94-100. [PMID: 29930829 DOI: 10.1002/ams2.16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 11/15/2013] [Indexed: 01/27/2023] Open
Abstract
AIM To investigate epidemiology of acute non-traumatic back pain using modern diagnostic methods in patients who visited an emergency room. METHODS The medical charts were retrospectively reviewed for all patients with back pain who were treated in our hospital. In addition, the patients were divided into two groups based on whether they were treated at the hospital or as outpatients. RESULTS There were 95 patients with non-traumatic acute back pain. Leading cause of back pain was ureterolithiasis (53 cases), followed by pyelonephritis (10), orthopedic disease including two cases of purulent spondylitis (24), aortic disease (3), pancreatitis (1), renal bleeding (1), adrenal bleeding (1), psoas abscess (1), and torsion of an ovarian tumor (1). All cases of pyelonephritis, aortic disease, purulent spondylitis, renal bleeding, adrenal bleeding, psoas abscess, and torsion of an ovarian tumor were treated in admission. Using a multiple logistic regression analysis, blood pressure, age, and body temperature were the only factors that were independently associated with whether the patient was admitted or treated as an outpatient. CONCLUSION This study showed that urological diseases are the most common cause of back pain in patients who visit the emergency room, followed by orthopedic disease. Older age, low blood pressure, and high body temperature were independently associated with the decision to admit the patient who might have lethal disease.
Collapse
Affiliation(s)
- Masataka Nagayama
- Department of Emergency and Disaster Medicine Juntendo University Tokyo Japan
| | - Youichi Yanagawa
- Department of Emergency and Disaster Medicine Juntendo University Tokyo Japan
| | - Koichiro Aihara
- Department of Emergency and Disaster Medicine Juntendo University Tokyo Japan
| | - Shin Watanabe
- Department of Emergency and Disaster Medicine Juntendo University Tokyo Japan
| | - Masaaki Takemoto
- Department of Emergency and Disaster Medicine Juntendo University Tokyo Japan
| | - Tomoko Nakazato
- Department of Emergency and Disaster Medicine Juntendo University Tokyo Japan
| | - Takashi Hashimoto
- Department of Emergency and Disaster Medicine Juntendo University Tokyo Japan
| | - Toshio Takayama
- Department of Emergency and Disaster Medicine Juntendo University Tokyo Japan
| | - Yuuji Takazawa
- Department of Orthopedics Juntendo University Tokyo Japan
| | - Toshiaki Iba
- Department of Emergency and Disaster Medicine Juntendo University Tokyo Japan
| | - Kazuo Kaneko
- Department of Orthopedics Juntendo University Tokyo Japan
| | - Hiroshi Tanaka
- Department of Emergency and Disaster Medicine Juntendo University Tokyo Japan
| |
Collapse
|
16
|
Chang C, Liu SP, Fang CH, He RS, Wang Z, Zhu YQ, Jiang SW. Effects of matrine on the proliferation of HT29 human colon cancer cells and its antitumor mechanism. Oncol Lett 2013; 6:699-704. [PMID: 24137393 PMCID: PMC3789009 DOI: 10.3892/ol.2013.1449] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2013] [Accepted: 06/21/2013] [Indexed: 12/14/2022] Open
Abstract
Matrine is one of the main active components that is extracted from the dry roots of Sophora flavescens. The compound has potent antitumor activity in various cancer cell lines. However, the anticancer activity of matrine in colon cancer cells remains unclear. The purpose of the present study was to investigate the effects of matrine on the growth of human colon cancer cells and the expression of the associated proteins. Cancer cell proliferation was measured by 3-(4,5-dimethylthiazolyl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. The cell cycle distribution and apoptosis were analyzed by flow cytometry (FCM). The activation of the caspases and the expression of pro-apoptotic and anti-apoptotic factors were examined using western blot analysis. Matrine was shown to significantly inhibit the proliferation of HT29 cells in a dose- and time-dependent manner, and also to reduce the percentage of cells in the G2/M phase, which was most frequently associated with an increase of cells arrested in the G0/G1 phase of the cell cycle. Western blot analysis revealed that matrine induced the activation of caspase-3 and -9 and the release of cytochrome C (Cyto C) from the mitochondria to the cytosol. Furthermore, the pro-apoptotic factor, Bax, was upregulated and the anti-apoptotic factor, Bcl-2, was downregulated, eventually leading to a reduction in the ratio of Bcl-2/Bax proteins. The results demonstrated that matrine inhibits proliferation and induces apoptosis of HT29 human cells in vitro. The induction of apoptosis appears to occur through the upregulation of Bax, the downregulation of Bcl-2, the release of Cyto C from the mitochondria to the cytosol and the activation of caspase-3 and caspase-9, which subsequently trigger major apoptotic cascades. Matrine has potent antitumor activity in HT29 cells and may be used as a novel effective reagent in the treatment of colon cancer.
Collapse
Affiliation(s)
- Cheng Chang
- Department of Gastroenterology, Huangshi Central Hospital of Hubei Polytechnic University, Huangshi, Hubei 435000, P.R. China
| | | | | | | | | | | | | |
Collapse
|